Tuesday, April 22, 2008 8:24:37 AM
21-Apr-2008
Change in Directors or Principal Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA) has received confirmation that D. Geoffrey Shulman, MD, the Company's founder, Chief Executive Officer from 1991 to 2007, and Chairman of the Board from 1991 to 2003 and since 2005, expects to be on short-term disability leave commencing sometime in June 2008 as a result of a serious health condition. DUSA expects that he will not continue as Chairman of the Board or as Chief Strategic Officer. However, DUSA expects that Dr. Shulman will remain on the Board of Directors and will continue as an employee of the company in a reduced role. DUSA and Dr. Shulman are in discussions regarding his ongoing employment arrangements.
Except for historical information, this report contains certain forward-looking statements that involve known and unknown risk and uncertainties. These forward-looking statements relate to the expectations that Dr. Shulman will change his role with the Company, that he will continue on the Board of Directors and as an employee, and the timing for the change to be implemented. These risks and uncertainties are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release. These factors include, without limitation, Dr. Shulman's medical condition, and other risks and uncertainties identified in DUSA's Form 10-K for the year ended December 31, 2007. Item 9.01 - Financial Statement and Exhibits.
Item No. Description
99.1 Press Release, dated April 21, 2008
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM